Seattle Genetics Inc. has reach a drug collaboration and license agreement with Pieris Pharmaceuticals Inc. worth up to $1.2 billion.

Seattle Genetics will pay Boston-based Pieris a $30 million up-front fee, royalties on some sales and up to $1.2 billion in milestone payments if the drugs reach their full potential.

The deal combines Seattle Genetics’ anti-drug conjugate technology and Pieris’ Anticalin technology to develop new antibody-Anticalin fusion proteins. 

“This partnership leverages…

Seattle Biz Journal
Seattle Genetics inks drug licensing deal worth up to .2 billion

Stay Current On Entrepreneurship

One email per week, all the latest content from the top rising business owners